 | | Vol. 11.10 – 16 March, 2022 |
| |
|
|
| Co-implantation with breast CSCs (BCSCs) decreased the tumor-initiating capacity yet increased metastasis of accompanying cancer cells, wherein DKK1 was identified as a pivotal factor secreted by BCSCs for such functions.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that collapsin response mediator protein 2A (CRMP2A) was unexpectedly and reversibly induced in cancer cells in response to multiple metabolic stresses, including low glucose and hypoxia, and inhibited EMT/stemness.
[Cell Reports] |
|
|
|
| Researchers demonstrated a novel mechanism whereby Wnt/β-catenin signaling pathway was regulated by different kinases in response to metabolic requirement of CSCs, and suggest that SIK2 inhibition may potentially be a strategy for eliminating breast CSCs.
[Oncogene] |
|
|
|
| Scientists reported the role of Lon in the response to cisplatin-induced mitochondrial DNA damage and oxidative stress, which conferred cancer cells on cisplatin resistance via modulating calcium levels in mitochondria and cytosol.
[Cell Death & Disease] |
|
|
|
| While azoxymethane delivery in vivo under non-adenoma-forming conditions yielded phenotypically normal mucosa and organoids derived thereof, niche injury ex vivo by progressive dextran sulfate sodium dose escalation facilitated outgrowth of Wnt-independent dysplastic organoids.
[JCI Insight] |
|
|
|
| The authors identified miR-148a as a targetable element upstream of pregnane X receptor (PXR) signaling in CSCs, which when over-expressed decreased PXR expression and impaired tumor relapse after chemotherapy in mouse tumor xenografts.
[Stem Cell Reports] |
|
|
|
| Scientists suggested that the asymmetric distribution of pericentrosomal CD133 endosomes induced the symmetry breaking of autophagic activity during cytokinesis in cooperation with nuclear β-catenin.
[Stem Cells] |
|
|
|
| Researchers revealed that the stemness-related gene AC01097.3 was closely associated with the survival of renal clear cell carcinoma patients.
[Scientific Reports] |
|
|
|
| The authors revealed that sialic acid removal and loading with CSC antigens induced significant molecular, morphological, and functional changes in dendritic cells (DCs) and that this new DC identity may be considered for future combined immunotherapy strategies against breast tumors.
[International Immunopharmacology] |
|
|
|
| RAB3B was identified as an up-regulated gene in both cancer stem-like sphere cells and prognostically poor hepatocellular carcinoma by RNA-sequencing.
[BMC Cancer] |
|
|
|
| Researchers evaluated diphenyleneiodonium as an anticancer drug by assessing its effect on an induced pluripotent stem-derived CSC model in both 2D and 3D culture conditions.
[Cell Biochemistry and Function] |
|
|
|
|
| The authors suggest that chronic diseases, including obesity and diabetes, establish the cancer-inducing niche that drives the undifferentiated/progenitor cells into CSCs, which then develop malignant tumours in vivo.
[British Journal of Cancer] |
|
|
|
| Investigators summarize what we know about tumor-associated macrophages (TAMs) and hepatocellular carcinoma (HCC), discussing the roles of TAMs in HCC development and the possible approaches for TAMs-targeted therapy as potential targets for HCC treatment.
[Biochemical Pharmacology] |
|
|
|
| Scientists review the evolution of tools to evaluate CSCs in liver cancers, discuss their contributions and limitations, as well as their combined and complementary utilization with techniques like human tumor organoid culture.
[Carcinogenesis] |
|
|
|
|
| Robert Gourdie, a cardiovascular scientist at the Fralin Biomedical Research Institute at Virginia Tech Carilion School of Medicine (VTC), is the first Virginia Tech researcher to receive an Outstanding Investigator Award from the National Institutes of Health (NIH).
[Virginia Tech] |
|
|
|
| AstraZeneca and Merck announced additional positive results from the Phase III OlympiA trial, where LYNPARZA demonstrated a statistically significant improvement in overall survival for the treatment of high-risk early breast cancer.
[Merck] |
|
|
|
| Merck announced that it will stop the Phase II KEYLYNK-010 trial investigating KEYTRUDA for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide.
[Imugene] |
|
|
|
|
| April 6 – 9, 2022
Heidelberg, Germany |
|
|
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| | Gilead Sciences – Foster City, California, United States |
|
|
|
| | Oregon Health and Science University – Portland, Oregon, United States |
|
|
|
| University of Virginia School of Medicine – Charlottesville, Virginia, United States |
|
|
|
| | University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
